Skip to main content

Adults Overdue for CRC Screen Rarely Receive Recommendation for Screening

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, Sept. 12, 2023 -- Only about one-quarter of adults who are overdue for colorectal cancer (CRC) screening receive a recommendation from their clinician, according to a research letter published online Sept. 12 in the Annals of Internal Medicine.

Jordan Baeker Bispo, Ph.D., M.P.H., from the American Cancer Society in Kennesaw, Georgia, and colleagues estimated the prevalence of receiving a clinician recommendation for CRC screening among underscreened U.S. adults using pooled data from the 2019 and 2021 National Health Interview Survey. A total of 5,022 adults who were eligible and overdue for CRC screening and had undergone a wellness visit in the past year were included in the analysis.

The researchers found that overall, 26.8 percent of these adults reported receiving a clinician recommendation for CRC screening. The prevalence varied from less than 10 to 32 percent for adults without a usual source of care and for those with a family income exceeding 400 percent of the federal poverty level, respectively. The prevalence of reporting a clinician recommendation for CRC screening was lower for non-Hispanic Asian, non-Hispanic Black, and Hispanic adults than non-Hispanic Whites (adjusted prevalence ratios, 0.53, 0.76, and 0.82, respectively) and was lower for those with less than a high school education versus those who had completed college and for uninsured adults versus those with private insurance (adjusted prevalence ratios, 0.76 and 0.51, respectively).

"The findings highlight a major communication gap about CRC prevention in the clinical setting," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.